Notably, high Nrf2 expression was also correlated with worse survival outcomes in cancer patients undergoing immune checkpoint inhibitor therapies, including anti‐PD1 and anti‐CTLA‐4 treatments, irrespective of cancer types (Figure 2A, middle). This evidence concerns the gene NFE2L2 and cancer.